These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 31665017)

  • 1. Treatment failure and hospital readmissions in severe COPD exacerbations treated with azithromycin versus placebo - a post-hoc analysis of the BACE randomized controlled trial.
    Vermeersch K; Belmans A; Bogaerts K; Gyselinck I; Cardinaels N; Gabrovska M; Aumann J; Demedts IK; Corhay JL; Marchand E; Slabbynck H; Haenebalcke C; Vermeersch S; Verleden GM; Troosters T; Ninane V; Brusselle GG; Janssens W;
    Respir Res; 2019 Oct; 20(1):237. PubMed ID: 31665017
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Azithromycin during Acute Chronic Obstructive Pulmonary Disease Exacerbations Requiring Hospitalization (BACE). A Multicenter, Randomized, Double-Blind, Placebo-controlled Trial.
    Vermeersch K; Gabrovska M; Aumann J; Demedts IK; Corhay JL; Marchand E; Slabbynck H; Haenebalcke C; Haerens M; Hanon S; Jordens P; Peché R; Fremault A; Lauwerier T; Delporte A; Vandenberk B; Willems R; Everaerts S; Belmans A; Bogaerts K; Verleden GM; Troosters T; Ninane V; Brusselle GG; Janssens W
    Am J Respir Crit Care Med; 2019 Oct; 200(7):857-868. PubMed ID: 31046405
    [No Abstract]   [Full Text] [Related]  

  • 3. The Belgian trial with azithromycin for acute COPD exacerbations requiring hospitalization: an investigator-initiated study protocol for a multicenter, randomized, double-blind, placebo-controlled trial.
    Vermeersch K; Gabrovska M; Deslypere G; Demedts IK; Slabbynck H; Aumann J; Ninane V; Verleden GM; Troosters T; Bogaerts K; Brusselle GG; Janssens W
    Int J Chron Obstruct Pulmon Dis; 2016; 11():687-96. PubMed ID: 27099485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial.
    Uzun S; Djamin RS; Kluytmans JA; Mulder PG; van't Veer NE; Ermens AA; Pelle AJ; Hoogsteden HC; Aerts JG; van der Eerden MM
    Lancet Respir Med; 2014 May; 2(5):361-8. PubMed ID: 24746000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-IL-5 therapies for chronic obstructive pulmonary disease.
    Donovan T; Milan SJ; Wang R; Banchoff E; Bradley P; Crossingham I
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013432. PubMed ID: 33295032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD).
    Herath SC; Normansell R; Maisey S; Poole P
    Cochrane Database Syst Rev; 2018 Oct; 10(10):CD009764. PubMed ID: 30376188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blood eosinophil count and GOLD stage predict response to maintenance azithromycin treatment in COPD patients with frequent exacerbations.
    Djamin RS; Bafadhel M; Uzun S; Russell REK; Ermens AAM; Kerstens R; Aerts JGJV; Pavord ID; van der Eerden MM
    Respir Med; 2019; 154():27-33. PubMed ID: 31203097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy.
    Han MK; Tayob N; Murray S; Dransfield MT; Washko G; Scanlon PD; Criner GJ; Casaburi R; Connett J; Lazarus SC; Albert R; Woodruff P; Martinez FJ
    Am J Respir Crit Care Med; 2014 Jun; 189(12):1503-8. PubMed ID: 24779680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Azithromycin and risk of COPD exacerbations in patients with and without Helicobacter pylori.
    Ra SW; Sze MA; Lee EC; Tam S; Oh Y; Fishbane N; Criner GJ; Woodruff PG; Lazarus SC; Albert R; Connett JE; Han MK; Martinez FJ; Aaron SD; Reed RM; Man SFP; Sin DD;
    Respir Res; 2017 May; 18(1):109. PubMed ID: 28558695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of macrolide maintenance therapy and bacterial colonisation on exacerbation frequency and progression of COPD (COLUMBUS): study protocol for a randomised controlled trial.
    Uzun S; Djamin RS; Kluytmans J; Van't Veer NE; Ermens AA; Pelle AJ; Mulder P; van der Eerden MM; Aerts J
    Trials; 2012 Jun; 13():82. PubMed ID: 22682323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD).
    Herath SC; Poole P
    Cochrane Database Syst Rev; 2013 Nov; (11):CD009764. PubMed ID: 24288145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Double-Blind, Randomized, Placebo-controlled Trial of Long-Term Doxycycline Therapy on Exacerbation Rate in Patients with Stable Chronic Obstructive Pulmonary Disease.
    Allinson JP; Vlies BH; Brill SE; Law M; Burnside G; Finney LJ; Alves-Moreira L; Donaldson GC; Calverley PMA; Walker PP; Wedzicha JA
    Am J Respir Crit Care Med; 2023 Sep; 208(5):549-558. PubMed ID: 37450935
    [No Abstract]   [Full Text] [Related]  

  • 13. Antibiotics for exacerbations of chronic obstructive pulmonary disease.
    Vollenweider DJ; Frei A; Steurer-Stey CA; Garcia-Aymerich J; Puhan MA
    Cochrane Database Syst Rev; 2018 Oct; 10(10):CD010257. PubMed ID: 30371937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial.
    Pascoe S; Barnes N; Brusselle G; Compton C; Criner GJ; Dransfield MT; Halpin DMG; Han MK; Hartley B; Lange P; Lettis S; Lipson DA; Lomas DA; Martinez FJ; Papi A; Roche N; van der Valk RJP; Wise R; Singh D
    Lancet Respir Med; 2019 Sep; 7(9):745-756. PubMed ID: 31281061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibiotics for exacerbations of chronic obstructive pulmonary disease.
    Vollenweider DJ; Jarrett H; Steurer-Stey CA; Garcia-Aymerich J; Puhan MA
    Cochrane Database Syst Rev; 2012 Dec; 12():CD010257. PubMed ID: 23235687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials.
    Bafadhel M; Peterson S; De Blas MA; Calverley PM; Rennard SI; Richter K; Fagerås M
    Lancet Respir Med; 2018 Feb; 6(2):117-126. PubMed ID: 29331313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study.
    Brightling CE; Bleecker ER; Panettieri RA; Bafadhel M; She D; Ward CK; Xu X; Birrell C; van der Merwe R
    Lancet Respir Med; 2014 Nov; 2(11):891-901. PubMed ID: 25208464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eosinophil counts in first COPD hospitalizations: a comparison of health service utilization.
    Bélanger M; Couillard S; Courteau J; Larivée P; Poder TG; Carrier N; Girard K; Vézina FA; Vanasse A
    Int J Chron Obstruct Pulmon Dis; 2018; 13():3045-3054. PubMed ID: 30319252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predicting response to benralizumab in chronic obstructive pulmonary disease: analyses of GALATHEA and TERRANOVA studies.
    Criner GJ; Celli BR; Singh D; Agusti A; Papi A; Jison M; Makulova N; Shih VH; Brooks L; Barker P; Martin UJ; Newbold P
    Lancet Respir Med; 2020 Feb; 8(2):158-170. PubMed ID: 31575508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial.
    Watz H; Tetzlaff K; Wouters EF; Kirsten A; Magnussen H; Rodriguez-Roisin R; Vogelmeier C; Fabbri LM; Chanez P; Dahl R; Disse B; Finnigan H; Calverley PM
    Lancet Respir Med; 2016 May; 4(5):390-8. PubMed ID: 27066739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.